Castle Biosciences Inc (CSTL)
Castle Biosciences, Inc. is a molecular diagnostics company focused on tests used in the assessment and management of several medical conditions, including dermatologic cancers, Barrett’s esophagus, atopic dermatitis, and uveal melanoma. Its product portfolio includes DecisionDx-Melanoma, TissueCypher, AdvanceAD-Tx, DecisionDx-SCC, MyPath Melanoma, and DecisionDx-UM. These tests are used in dermatology and gastroenterology settings and are designed to support clinical decision-making through risk assessment and diagnosis-related insights. Castle Biosciences was incorporated in 2007 and is headquartered in Friendswood, Texas. The company’s common stock is listed on NASDAQ under the ticker CSTL.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CSTL
|
$26.79
|
11.0% Upside
|
Fair
|
$42.78
|
77.2% Upside
|
Bargain
|
Great
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-57.3x
|
1.6x
|
2.2x
|
724.7 M
|
509.9 M
|
4.8%
|
88.3%
|
5.5
|
—
|
-35.2%
|
